Physician profile
Sonal Arora
NPI 1477592327
$984.56
in general payments reported to CMS, 2019-2025
21 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.47 · 2020: $21.04 · 2021: $111 · 2022: $37.91 · 2023: $26.54 · 2024: $239 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735 · Education: $21.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.34 |
| Education | $21.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $179.93 | 2020-2024 | Acthar |
| Glaxosmithkline, LLC. | $146.09 | 2021-2025 | Nucala |
| Pulmonx Corporation | $112.85 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Resmed Corp | $58.38 | 2025 | |
| United Therapeutics Corporation | $56.90 | 2025 | Tyvaso |
| Ani Pharmaceuticals, INC. | $46.10 | 2025 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $44.77 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $44.04 | 2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $41.46 | 2024 | Uptravi, Opsumit |
| Circassia INC. | $37.01 | 2025 | Niox |
| Sunovion Pharmaceuticals INC. | $35.66 | 2019 | |
| Genzyme Corporation | $31.68 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $26.54 | 2023 | Dupixent |
| Avadel Cns Pharmaceuticals, LLC | $20.92 | 2025 | Lumryz |
| Harmony Biosciences LLC | $20.13 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $19.83 | 2021 | |
| Viatris Specialty LLC | $18.59 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $15.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.61 | 2019 | |
| Genentech USA, INC. | $11.20 | 2019 | |
| Inogen, INC. | $5.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.